Primary and Compensatory Roles for RB Family Members at Cell Cycle Gene Promoters That Are Deacetylated and Downregulated in Doxorubicin-Induced Senescence of Breast Cancer Cells

REFERENCES

• Baus, F., V. Gire, D. Fisher, J. Piette, and V. Dulic. 2003. Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J. 22:3992–4002.
   PubMedGoogle Scholar
• Berns, A. 2002. Senescence: a companion in chemotherapy? Cancer Cell 1:309–311.
   PubMedGoogle Scholar
• Blais, A., and B. D. Dynlacht. 2004. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr. Opin. Genet. Dev. 14:527–532.
   PubMedGoogle Scholar
• Bringold, F., and M. Serrano. 2000. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol. 35:317–329.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J., K. Moberg, S. D. Boyd, Y. Taya, T. Jacks, and J. A. Lees. 1999. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc. Natl. Acad. Sci. USA 96:1002–1007.
   PubMed Web of Science ®Google Scholar
• Chang, B. D., E. V. Broude, M. Dokmanovic, H. Zhu, A. Ruth, Y. Xuan, E. S. Kandel, E. Lausch, K. Christov, and I. B. Roninson. 1999. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59:3761–3767.
   PubMed Web of Science ®Google Scholar
• Chang, B. D., Y. Xuan, E. V. Broude, H. Zhu, B. Schott, J. Fang, and I. B. Roninson. 1999. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18:4808–4818.
   PubMed Web of Science ®Google Scholar
• Dalton, S. 1992. Cell cycle regulation of the human cdc2 gene. EMBO J. 11:1797–1804.
   PubMed Web of Science ®Google Scholar
• Elmore, L. W., C. W. Rehder, X. Di, P. A. McChesney, C. K. Jackson-Cook, D. A. Gewirtz, and S. E. Holt. 2002. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 277:35509–35515.
   PubMed Web of Science ®Google Scholar
• Erdmann, J. 2005. Cancer's big sleep: senescence may be potential target for cancer therapies. J. Natl. Cancer Inst. 97:89–91.
   PubMedGoogle Scholar
• Eward, K. L., M. N. Van Ert, M. Thornton, and C. E. Helmstetter. 2004. Cyclin mRNA stability does not vary during the cell cycle. Cell Cycle 3:1057–1061.
   PubMedGoogle Scholar
• Ferreira, R., I. Naguibneva, L. L. Pritchard, S. Ait-Si-Ali, and A. Harel-Bellan. 2001. The Rb/chromatin connection and epigenetic control: opinion. Oncogene 20:3128–3133.
   PubMed Web of Science ®Google Scholar
• Flatt, P. M., L. J. Tang, C. D. Scatena, S. T. Szak, and J. A. Pietenpol. 2000. p53 regulation of G2 checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 20:4210–4223.
   PubMed Web of Science ®Google Scholar
• Frank, S. R., M. Schroeder, P. Fernandez, S. Taubert, and B. Amati. 2001. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 15:2069–2082.
   PubMed Web of Science ®Google Scholar
• Frolov, M. V., and N. J. Dyson. 2004. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell Sci. 117:2173–2181.
   PubMed Web of Science ®Google Scholar
• Grill, C., F. Gheyas, P. Dayananth, W. Jin, W. Ding, P. Qiu, L. Wang, R. J. Doll, and J. M. English. 2004. Analysis of the ERK1,2 transcriptome in mammary epithelial cells. Biochem. J. 381:635–644.
   PubMedGoogle Scholar
• Han, Z., W. Wei, S. Dunaway, J. W. Darnowski, P. Calabresi, J. Sedivy, E. A. Hendrickson, K. V. Balan, P. Pantazis, and J. H. Wyche. 2002. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277:17154–17160.
   PubMed Web of Science ®Google Scholar
• Harbour, J. W., and D. C. Dean. 2000. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2393–2409.
   PubMed Web of Science ®Google Scholar
• Harrington, E. A., J. L. Bruce, E. Harlow, and N. Dyson. 1998. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. USA 95:11945–11950.
   PubMed Web of Science ®Google Scholar
• Jackson, J. G., P. St Clair, M. X. Sliwkowski, and M. G. Brattain. 2004. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 64:2601–2609.
   PubMed Web of Science ®Google Scholar
• Jackson, M. W., M. K. Agarwal, J. Yang, P. Bruss, T. Uchiumi, M. L. Agarwal, G. R. Stark, and W. R. Taylor. 2005. p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J. Cell Sci. 118:1821–1832.
   PubMed Web of Science ®Google Scholar
• Kaeser, M. D., and R. D. Iggo. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99:95–100.
   PubMed Web of Science ®Google Scholar
• Knudsen, K. E., D. Booth, S. Naderi, Z. Sever-Chroneos, A. F. Fribourg, I. C. Hunton, J. R. Feramisco, J. Y. Wang, and E. S. Knudsen. 2000. RB-dependent S-phase response to DNA damage. Mol. Cell. Biol. 20:7751–7763.
   PubMed Web of Science ®Google Scholar
• Knudsen, K. E., A. F. Fribourg, M. W. Strobeck, J. M. Blanchard, and E. S. Knudsen. 1999. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. J. Biol. Chem. 274:27632–27641.
   PubMed Web of Science ®Google Scholar
• Lee, E. Y., H. To, J. Y. Shew, R. Bookstein, P. Scully, and W. H. Lee. 1988. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218–221.
   PubMed Web of Science ®Google Scholar
• Litovchick, L., A. Chestukhin, and J. A. DeCaprio. 2004. Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence. Mol. Cell. Biol. 24:8970–8980.
   PubMedGoogle Scholar
• Narita, M., S. Nunez, E. Heard, A. W. Lin, S. A. Hearn, D. L. Spector, G. J. Hannon, and S. W. Lowe. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703–716.
   PubMed Web of Science ®Google Scholar
• Paggi, M. G., and A. Giordano. 2001. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res. 61:4651–4654.
   PubMedGoogle Scholar
• Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
   PubMed Web of Science ®Google Scholar
• Roberson, R. S., S. J. Kussick, E. Vallieres, S. Y. Chen, and D. Y. Wu. 2005. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 65:2795–2803.
   PubMed Web of Science ®Google Scholar
• Roninson, I. B. 2002. Tumor senescence as a determinant of drug response in vivo. Drug Resist. Update 5:204–208.
   PubMed Web of Science ®Google Scholar
• Schmitt, C. A., J. S. Fridman, M. Yang, S. Lee, E. Baranov, R. M. Hoffman, and S. W. Lowe. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335–346.
   PubMed Web of Science ®Google Scholar
• Shay, J. W., and I. B. Roninson. 2004. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919–2933.
   PubMed Web of Science ®Google Scholar
• Slebos, R. J., M. H. Lee, B. S. Plunkett, T. D. Kessis, B. O. Williams, T. Jacks, L. Hedrick, M. B. Kastan, and K. R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 91:5320–5324.
   PubMed Web of Science ®Google Scholar
• Smith, E. J., G. Leone, J. DeGregori, L. Jakoi, and J. R. Nevins. 1996. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol. Cell. Biol. 16:6965–6976.
   PubMed Web of Science ®Google Scholar
• Smith, E. J., G. Leone, and J. R. Nevins. 1998. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ. 9:297–303.
   PubMedGoogle Scholar
• Stark, G. R., and W. R. Taylor. 2004. Analyzing the G2/M checkpoint. Methods Mol. Biol. 280:51–82.
   PubMedGoogle Scholar
• Stein, G. H., M. Beeson, and L. Gordon. 1990. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 249:666–669.
   PubMed Web of Science ®Google Scholar
• Takahashi, Y., J. B. Rayman, and B. D. Dynlacht. 2000. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 14:804–816.
   PubMed Web of Science ®Google Scholar
• Taubert, S., C. Gorrini, S. R. Frank, T. Parisi, M. Fuchs, H. M. Chan, D. M. Livingston, and B. Amati. 2004. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol. Cell. Biol. 24:4546–4556.
   PubMed Web of Science ®Google Scholar
• Taylor, W. R., A. H. Schonthal, J. Galante, and G. R. Stark. 2001. p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J. Biol. Chem. 276:1998–2006.
   PubMed Web of Science ®Google Scholar
• Tedesco, D., J. Lukas, and S. I. Reed. 2002. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev. 16:2946–2957.
   PubMed Web of Science ®Google Scholar
• te Poele, R. H., A. L. Okorokov, L. Jardine, J. Cummings, and S. P. Joel. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62:1876–1883.
   PubMed Web of Science ®Google Scholar
• Tommasi, S., and G. P. Pfeifer. 1995. In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol. Cell. Biol. 15:6901–6913.
   PubMedGoogle Scholar
• Wang, L., Q. Wu, P. Qiu, A. Mirza, M. McGuirk, P. Kirschmeier, J. R. Greene, Y. Wang, C. B. Pickett, and S. Liu. 2001. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J. Biol. Chem. 276:43604–43610.
   PubMedGoogle Scholar
• Wosikowski, K., J. T. Regis, R. W. Robey, M. Alvarez, J. T. Buters, J. M. Gudas, and S. E. Bates. 1995. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 6:1395–1403.
   PubMedGoogle Scholar
• Zhang, H. S., and D. C. Dean. 2001. Rb-mediated chromatin structure regulation and transcriptional repression. Oncogene 20:3134–3138.
   PubMedGoogle Scholar
• Zhu, L., E. Xie, and L. S. Chang. 1995. Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol. Cell. Biol. 15:3552–3562.
   PubMed Web of Science ®Google Scholar